BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20956109)

  • 1. Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment.
    Tougeron D; Wierzbicka-Hainaut E; Osdoit S; Chagneau-Derrode C; Yacoub M; Silvain C
    Eur J Dermatol; 2010; 20(6):854-6. PubMed ID: 20956109
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperkeratosis of nipple skin during sorafenib treatment.
    Frigerio M; Santi V; Di Micoli A; Trevisani F
    Dig Liver Dis; 2009 Aug; 41(8):611. PubMed ID: 19303375
    [No Abstract]   [Full Text] [Related]  

  • 3. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
    Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
    Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib-induced acute pancreatitis.
    Saadati H; Saif MW
    JOP; 2010 May; 11(3):283-4. PubMed ID: 20442531
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatocellular carcinoma management in the era of sorafenib].
    Rosmorduc O
    Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
    Liang CP; Yang CS; Shen JL; Chen YJ
    Br J Dermatol; 2011 Aug; 165(2):443-5. PubMed ID: 21495998
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
    Mancuso A; Airoldi A; Vigano R; Pinzello G
    Dig Liver Dis; 2011 Sep; 43(9):754. PubMed ID: 21641889
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib-induced bilateral osteonecrosis of femoral heads.
    Guillet M; Walter T; Scoazec JY; Vial T; Lombard-Bohas C; Dumortier J
    J Clin Oncol; 2010 Jan; 28(2):e14. PubMed ID: 19884542
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib-induced hepatic encephalopathy.
    Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
    Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
    Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
    Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma.
    Lucas E; Aubourg A; Bacq Y; Perarnau JM
    Dig Liver Dis; 2011 Nov; 43(11):920. PubMed ID: 21763223
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 14. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet count less than SHARP: what does a case series reveal?
    Saif MW
    Expert Opin Drug Saf; 2010 Jan; 9(1):1-8. PubMed ID: 20001607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All that glitters: sorafenib.
    Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
    Intern Med; 2011; 50(7):797. PubMed ID: 21467725
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
    Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up.
    Di Benedetto F; Tarantino G; Montalti R; Ballarin R; D'Amico G; Berretta M; Gerunda GE
    Transpl Int; 2011 Nov; 24(11):e97; author reply e98-9. PubMed ID: 21910763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.